Coordinated regulation of myeloid cells by tumours

Dmitry I. Gabrilovich; Suzanne Ostrand-Rosenberg; Vincenzo Bronte

doi:10.1038/nri3175

journal article Mar 22, 2012

Coordinated regulation of myeloid cells by tumours

Dmitry I. Gabrilovich

Suzanne Ostrand-Rosenberg

Vincenzo Bronte

Nature Reviews Immunology Vol. 12 No. 4 pp. 253-268 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/nri3175

Topics

No keywords indexed for this article. Browse by subject →

References

201

[1]

Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39–51 (2010). 10.1016/j.cell.2010.03.014

[2]

Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunol. 11, 889–896 (2010). 10.1038/ni.1937

[3]

Coussens, L. M. & Pollard, J. W. Leukocytes in mammary development and cancer. Cold Spring Harb. Perspect. Biol. 3, a003285 (2011). 10.1101/cshperspect.a003285

[4]

Khazaie, K. et al. The significant role of mast cells in cancer. Cancer Metastasis Rev. 30, 45–60 (2011). 10.1007/s10555-011-9286-z

[5]

Liu, K. & Nussenzweig, M. C. Origin and development of dendritic cells. Immunol. Rev. 234, 45–54 (2010). 10.1111/j.0105-2896.2009.00879.x

[6]

Fogg, D. K. et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science 311, 83–87 (2006). 10.1126/science.1117729

[7]

Onai, N. et al. Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nature Immunol. 8, 1207–1216 (2007). 10.1038/ni1518

[8]

Naik, S. H. et al. Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nature Immunol. 8, 1217–1226 (2007). 10.1038/ni1522

[9]

Shortman, K. & Heath, W. R. The CD8+ dendritic cell subset. Immunol. Rev. 234, 18–31 (2010). 10.1111/j.0105-2896.2009.00870.x

[10]

Idoyaga, J. & Steinman, R. M. SnapShot: dendritic cells. Cell 146, 660–660.e2 (2011). 10.1016/j.cell.2011.08.010

[11]

Swiecki, M. & Colonna, M. Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol. Rev. 234, 142–162 (2010). 10.1111/j.0105-2896.2009.00881.x

[12]

Dominguez, P. M. & Ardavin, C. Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol. Rev. 234, 90–104 (2010). 10.1111/j.0105-2896.2009.00876.x

[13]

Gabrilovich, D. I. The mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Rev. Immunol. 4, 941–952 (2004). 10.1038/nri1498

[14]

Pinzon-Charry, A. et al. Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer. Br. J. Cancer 97, 1251–1259 (2007). 10.1038/sj.bjc.6604018

[15]

Perrot, I. et al. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J. Immunol. 178, 2763–2769 (2007). 10.4049/jimmunol.178.5.2763

[16]

Bellone, G. et al. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J. Immunol. 177, 3448–3460 (2006). 10.4049/jimmunol.177.5.3448

[17]

Lee, B. N. et al. Deficiencies in myeloid antigen-presenting cells in women with cervical squamous intraepithelial lesions. Cancer 107, 999–1007 (2006). 10.1002/cncr.22092

[18]

Ormandy, L. A. et al. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J. Gastroenterol. 12, 3275–3282 (2006). 10.3748/wjg.v12.i20.3275

[19]

Pinzon-Charry, A., Maxwell, T. & Lopez, J. A. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol. Cell Biol. 83, 451–461 (2005). 10.1111/j.1440-1711.2005.01371.x

[20]

Mancino, A. et al. Divergent effects of hypoxia on dendritic cell functions. Blood 112, 3723–3734 (2008). 10.1182/blood-2008-02-142091

[21]

Elia, A. R. et al. Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile. J. Leukoc. Biol. 84, 1472–1482 (2008). 10.1189/jlb.0208082

[22]

Yang, M. et al. HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia. Immunol. Cell Biol. 88, 165–171 (2010). 10.1038/icb.2009.77

[23]

Novitskiy, S. V. et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 112, 1822–1831 (2008). 10.1182/blood-2008-02-136325

[24]

Gottfried, E. et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 107, 2013–2021 (2006). 10.1182/blood-2005-05-1795

[25]

Herber, D. L. et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nature Med. 16, 880–886 (2010). 10.1038/nm.2172

[26]

Ghiringhelli, F. et al. Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202, 919–929 (2005). 10.1084/jem.20050463

[27]

Lin, A., Schildknecht, A., Nguyen, L. T. & Ohashi, P. S. Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol. Lett. 127, 77–84 (2010). 10.1016/j.imlet.2009.09.003

[28]

Norian, L. A. et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res. 69, 3086–3094 (2009). 10.1158/0008-5472.can-08-2826

[29]

Watkins, S. K. et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J. Clin. Invest. 121, 1361–1372 (2011). 10.1172/jci44325

[30]

Dumitriu, I. E., Dunbar, D. R., Howie, S. E., Sethi, T. & Gregory, C. D. Human dendritic cells produce TGF-β1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 182, 2795–2807 (2009). 10.4049/jimmunol.0712671

[31]

Liu, Q. et al. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J. Immunol. 182, 6207–6216 (2009). 10.4049/jimmunol.0803926

[32]

Lee, J. R. et al. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab. Invest. 83, 1457–1466 (2003). 10.1097/01.lab.0000090158.68852.d1

[33]

Munn, D. H. et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114, 280–290 (2004). 10.1172/jci21583

[34]

Baban, B. et al. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J. Immunol. 183, 2475–2483 (2009). 10.4049/jimmunol.0900986

[35]

Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nature Rev. Immunol. 8, 958–969 (2008). 10.1038/nri2448

[36]

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

A MANTOVANI, S SOZZANI, M LOCATI et al.

Trends in Immunology 2002 10.1016/s1471-4906(02)02302-5

[37]

Mantovani, A., Sica, A., Allavena, P., Garlanda, C. & Locati, M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol. 70, 325–330 (2009). 10.1016/j.humimm.2009.02.008

[38]

Mantovani, A. & Sica, A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22, 231–237 (2010). 10.1016/j.coi.2010.01.009

[39]

Steidl, C. et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med. 362, 875–885 (2010). This study identified a gene signature of TAMs that was associated with primary treatment failure in patients with Hodgkin's lymphoma, and demonstrated that the number of macrophages in patients with Hodgkin's lymphoma is prognostic of clinical outcome. 10.1056/nejmoa0905680

[40]

Lin, E. Y. et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 66, 11238–11246 (2006). 10.1158/0008-5472.can-06-1278

[41]

Qian, B. et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 4, e6562 (2009). This study demonstrated that macrophages have a crucial role in metastatic cell seeding and in the progression of metastatic disease. 10.1371/journal.pone.0006562

[42]

Zheng, Y. et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114, 3625–3628 (2009). 10.1182/blood-2009-05-220285

[43]

Alternative Activation of Macrophages: Mechanism and Functions

Siamon Gordon, Fernando O. Martinez

Immunity 2010 10.1016/j.immuni.2010.05.007

[44]

DeNardo, D. G. et al. CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16, 91–102 (2009). This study demonstrated that, in transgenic mice with mammary carcinomas, TAMs develop a pro-tumour and pro-metastatic phenotype in response to CD4+ T cell-derived IL-4. These findings demonstrate that the adaptive immune system plays a substantial part in driving the pro-tumour activity of the innate immune system. 10.1016/j.ccr.2009.06.018

[45]

Murai, M. et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nature Immunol. 10, 1178–1184 (2009). 10.1038/ni.1791

[46]

Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 10, 942–949 (2004). 10.1038/nm1093

[47]

Torroella-Kouri, M. et al. Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res. 69, 4800–4809 (2009). 10.1158/0008-5472.can-08-3427

[48]

Kuang, D. M. et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206, 1327–1337 (2009). This study demonstrated that CD68+ monocytes in the peritumoural stroma of patients with hepatocellular carcinoma express PDL1, induce T cell anergy, promote tumour progression and are associated with poor survival. 10.1084/jem.20082173

[49]

Rodriguez, P. C. et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64, 5839–5849 (2004). 10.1158/0008-5472.can-04-0465

[50]

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

Bin-Zhi Qian, Jiufeng Li, Hong Zhang et al.

Nature 2011 10.1038/nature10138

Showing 50 of 201 references

Cited By

3,098

The role of myeloid-derived suppressor cells in Sjögren's disease

Liang Jin, Chenxu Yang · 2026

Autoimmunity Reviews

Systemically inducing trained immunity overcomes solid tumors’ immunosuppressive microenvironment

Bram Priem, Lisa Willemsen · 2026

Science Advances

Myeloid-derived suppressor cells promote therapy-induced resistance in prostate cancer

Anlin Liu, Pan Song · 2026

International Journal of Surgery

Intratumoral heterogeneity and immunotherapy resistance: clinical implications

B.P. Keenan, M. Yadav · 2026

Annals of Oncology

Interplay between the complement system and other immune pathways in the tumor microenvironment

Cecilia Garlanda, Monica Dambra · 2025

Seminars in Immunology

Bridging the gap: ferroptosis of immune cells in the tumor microenvironment

Weijing Wang, Huiyao Li · 2025

Frontiers in Immunology

Exosomes delivering miR-129-5p combined with sorafenib ameliorate hepatocellular carcinoma progression via the KCTD1/HIF-1α/VEGF pathway

Xinyu Zhu, Zhiwei Li · 2025

Cellular Oncology

Recent developments in myeloid immune modulation in cancer therapy

Sepideh Parvanian, Xinying Ge · 2025

Trends in Cancer

Myeloid-derived suppressor cells in cancer and cancer therapy

Samantha A. Lasser, Feyza G. Ozbay Kurt · 2024

Nature Reviews Clinical Oncology

Immune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling

Li-Ying Wu, Su-Ho Park · 2024

Cancers

Curcumin Suppresses M2 Macrophage-derived Paclitaxel Chemoresistance through Inhibition of PI3K-AKT/STAT3 Signaling

Bhawna Deswal, Urmi Bagchi · 2024

Anti-Cancer Agents in Medicinal Che...

Therapeutic targeting of cGAS–STING pathway in lung cancer

Jinli Wang, Lumin Xing · 2024

Cell Biology International

Comprehensive Analysis of Lung Adenocarcinoma and Brain Metastasis through Integrated Single-Cell Transcriptomics

Vanessa G. P. Souza, Nikita Telkar · 2024

International Journal of Molecular...

Heterogeneity and tumoral origin of medulloblastoma in the single-cell era

Hui Sheng, Haotai Li · 2024

Oncogene

Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance

Yumin Fu, Xinyu Guo · 2024

eLife

Cancer stem cells release interleukin-33 within large oncosomes to promote immunosuppressive differentiation of macrophage precursors

Hannah L. Erickson, Sachiko Taniguchi · 2024

Immunity

Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy

Qiang Lu, Dongquan Kou · 2024

Journal of Hematology & Oncolog...

MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target

Haoyu Liu, Zhicheng Wang · 2023

Frontiers in Immunology

Nicotinamide N-methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma

Yang Li, Bo Yang · 2023

Hepatology

How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation

Qianyu Wang, Xiaofei Shen · 2023

International Journal of Cancer

Metrics

3,098

Citations

201

References

Details

Published: Mar 22, 2012
Vol/Issue: 12(4)
Pages: 253-268
License: View

Authors

D

Dmitry I. Gabrilovich

S

Suzanne Ostrand-Rosenberg

Department of Biological Sciences, University of Maryland Baltimore County , Baltimore, MD 21250

V

Vincenzo Bronte

Department of Pathology and Diagnostics, Verona University, 37134 Verona, Italy 5

Cite This Article

Dmitry I. Gabrilovich, Suzanne Ostrand-Rosenberg, Vincenzo Bronte (2012). Coordinated regulation of myeloid cells by tumours. Nature Reviews Immunology, 12(4), 253-268. https://doi.org/10.1038/nri3175

Coordinated regulation of myeloid cells by tumours

You May Also Like